Roxb. rhizome is a fork medicine mainly used in South and Southeast Asia. In present study, the hypoglycaemic effects of the ethanolic extract of . rhizome were demonstrated both on α-glucosidase assay and streptozotocin (STZ)-induced postprandial hyperglycaemia in mice. Furthermore, six labdane diterpenes, amoxanthin A (1), ottensinin (2), coronarin D (3), coronarin D methyl ether (4), isocoronarin D (5), and zerumin (6), were isolated from its ethyl acetate sub-fraction with the guidance of α-glucosidase inhibitory activity. Among these compounds, 2 and 6 exhibited significant inhibitory effect on α-glucosidase, as well as on STZ-induced high postprandial blood glucose levels in mice. Additionally, molecular docking analysis revealed that 2 and 6 could firmly bind to the active sites of α-glucosidase. These results suggest that compounds 2 and 6 are the main anti-hyperglycaemic agents present in . , which may demonstrate potential beneficial effects in diabetes management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14786419.2021.1903006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland.
Swiss Med Wkly
January 2025
Cancer Center und Research Center, Cantonal Hospital Graubünden, Chur, Switzerland.
Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.
View Article and Find Full Text PDFEssential Oil Variability of Juniperus oxycedrus s.l. Taxa in Southeast Europe - a Chemophenetic Approach.
Chem Biodivers
January 2025
University of Belgrade Faculty of Biology: Univerzitet u Beogradu Bioloski Fakultet, Plant morphology and systematics, Takovska 43, Belgrade, 11000, Belgrade, SERBIA.
The essential oil composition of 14 natural populations of two Juniperus oxycedrus s.l. taxa (J.
View Article and Find Full Text PDFThunb.: a review on phytochemical composition and pharmacological activities.
Front Pharmacol
January 2025
School Hospital, Guizhou Medical University, Guiyang, China.
Thunb. (. ) is a shrub or tree of the genus , family Lamiaceae, which is widely distributed in China, Korea, India, Japan and Philippines.
View Article and Find Full Text PDFA synchronous occurrence of breast cancer and pleural mesothelioma: a case report.
J Med Case Rep
January 2025
Kabir Medical College, Peshawar, Pakistan.
Background: Malignant mesotheliomas are aggressive forms of tumors arising from mesothelial cells. The most common type is malignant pleural mesothelioma, which progresses rapidly and leads to pleural effusion. It typically affects older men and is strongly associated with asbestos exposure.
View Article and Find Full Text PDFStudy protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
BMC Cancer
January 2025
Barts Cancer Institute and Wolfson Institute of Public Health, Mary University of London, John Vane Science Centre, Charterhouse Square, London, Queen, EC1M 6BQ, UK.
Background: Pancreatic cancer (PDAC: pancreatic ductal adenocarcinoma, the commonest form), a lethal disease, is best treated with surgical excision but is feasible in less than a fifth of patients. Around a third of patients presentlocally advanced, inoperable, non-metastatic (laPDAC), whose stadrd of care is palliative chemotherapy; a small minority are down-sized sufficiently to enable surgical excision. We propose a phase II clinical trial to test whether a combination of standard chemotherapy (gemcitabine & nab-Paclitaxel: GEM-NABP) and repurposing All Trans Retinoic Acid (ATRA) to target the stroma may extend progression-free survival and enable successful surgical resection for patients with laPDAC, since data from phase IB clinical trial demonstrate safety of GEM-NABP-ATRA combination to patients with advanced PDAC with potential therapeutic benefit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!